Genetic Therapies Bootcamp: Foundations, Frontiers, and Clinical Engagement OnDemand-03-10 17-15 314-317 Joint Closing Address The Evolution of Gene Therapy ” Milestones, Challenges, a

03-10 17-15 314-317 Joint Closing Address The Evolution of Gene Therapy ” Milestones, Challenges, a

Video Transcription

Video Summary

Dr. Pierce, an expert in ophthalmology and inherited retinal diseases, discussed the evolution and future challenges of gene therapies, particularly for rare genetic disorders. He highlighted successes like the FDA-approved Luxturna for retinal degeneration and CRISPR-Cas9 trials targeting CEP290. He emphasized gene therapy milestones, including therapies for spinal muscular atrophy and sickle cell disease, while cautioning about inflammation and toxicity issues associated with viral delivery systems like AAV. A key theme was reconsidering the traditional Mendelian view of rare diseases as strictly deterministic; his population-based studies using large biobanks revealed that many individuals carrying “pathogenic” variants do not express disease, showing 10-30% penetrance, prompting the need to explore genetic modifiers and environmental factors influencing disease expression. This has crucial implications for genetic testing, therapy development, and newborn screening. Dr. Pierce called for improved clinical trial endpoints, better understanding of biology, novel delivery technologies, and collaborative efforts to study genotype-phenotype correlations and improve therapy success. He also noted the FDA’s draft guidance on targeted treatments with biomarkers may accelerate rare disease drug approvals. Overall, his talk underscored that while gene therapies have transformative potential, addressing inflammation, defining accurate endpoints, and integrating complex genetic insights are essential steps for the field's advancement.

Keywords

gene therapy

inherited retinal diseases

Luxturna

CRISPR-Cas9

CEP290

AAV viral delivery

Mendelian genetics

genetic modifiers

FDA rare disease guidance